BOTHELL, Wash., Nov. 12 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. announced today that representatives from its research and development team will be attending the 2008 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting to be held November, 16-20, 2008 at the Georgia World Congress Center in Atlanta, GA.
SCOLR Pharma will be exhibiting at the AAPS show in booth #708 where its representatives will be available to engage the pharmaceutical scientific community about applications of its patented, CDT(R) oral drug delivery technologies. The Company will also make a total of eight poster presentations over three days, one of which will focus on its 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. Ibuprofen is an analgesic that is sold in immediate-dose products as Advil(R) and Motrin(R), among others, as well as generically. SCOLR recently reported favorable top-line results from its pivotal Phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 mg ER ibuprofen for the OTC market. The trial incorporated FDA special protocol assessment design elements, met both co-primary endpoints (p<0.0001), and had no significant adverse events.
SCOLR Pharma will make the following eight poster presentations at the 2008 AAPS annual meeting:
About SCOLR Pharma
Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma’s corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.
CONTACT: Investors, Kevin McGrath of Cameron Associates, +1-212-245-4577,
Kevin@cameronassoc.com
Web site: http://www.scolr.com//
